Neonatal gastrointestinal mucormycosis mimicking necrotizing enterocolitis

Nissen,; Jana, A K; Mj, Cole; Jm, Grierson; Gilbert, G. L.

doi:10.1111/j.1651-2227.1999.tb01035.x

Cited by 19 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 200 cases of GI mucormycosis in non‐classical immunosuppressed or apparently immunocompetent hosts reported during 1948 through 2017 in English literature . The case details could be retrieved for 176 cases.…”

Section: Resultsmentioning

confidence: 99%

Gastrointestinal mucormycosis in apparently immunocompetent hosts—A review

Kaur

Ghosh

Rudramurthy

et al. 2018

Mycoses

View full text Add to dashboard Cite

The diagnosis of gastrointestinal (GI) mucormycosis is always a challenge due to its non-specific clinical presentations and often diagnosed at autopsy. Recently increased number of GI mucormycosis has been reported in immunocompetent hosts and during 1948 through 2017, 200 cases of GI mucormycosis are available in literature. We could review 176 cases where case details were available. Majority (50.6%) of the cases were reported from Asia. The disease is nearly equally recorded in adults and paediatric population. The infection commonly affected the intestine (64.2%) followed by stomach (33%). A significant improvement in antemortem diagnosis was noted since 2001. Rhizopus species were the predominant (67.5%) aetiological agents. Amphotericin B was the most commonly used drug (93.4%). Despite improvement of antemortem diagnosis and therapy, the mortality was 60.5% and 67.5% in adults and children respectively. Combined medical and surgical therapy (reported in 47.8% patients) had significantly better survival rate than those receiving either of them. Analysing the clinical presentations, we propose to suspect GI mucormycosis in a malnourished/ dehydrated child (especially premature neonate) with history of exposure to broad-spectrum antibiotics or formula/spoon feeding and presenting with mass in abdomen, abdominal distension or bilious vomiting; and an adult presenting with abdominal distension, fever or GI bleed with underlying risk factors for mucormycosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Gastrointestinal mucormycosis in apparently immunocompetent hosts—A review

Kaur

Ghosh

Rudramurthy

et al. 2018

Mycoses

View full text Add to dashboard Cite

show abstract

“…Simulated acidotic condition decreased the iron binding Potency of Sera obtain from normal human suggested that acidosis is temporary disrupt the potency of transferrin to bind on iron site. Patient having diabetic ketoacidosis has developed susceptibility for Mucormycosis and increased serum iron 17 .…”

Section: Pathophysiologymentioning

confidence: 99%

A Review on Mucormycosis with recent pharmacological treatment

Shinde¹,

Kore

2021

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Mucormycosis is antifungal eye infection difficult to manage this infection with limited use of diagnostic tool and therapeutic option, but previous literature studied diagnostic strategies and evaluate the potency of antifungal agent as a treatment option. Mucormycosis was difficult to study on imaging studies. Surgery plus antifungal therapy of high dose yields greater survival rates. Mucorales are most widely resisted to the used as an antifungal agent. Amphotericin -B were kept for de-escalation refractory therapy whereas, patient’s intolerant to Amphotericin B. Keywords: Mucormycosis, amphotericin, antifungal agents

show abstract

“…[17] The clinical features of GIMN are often mistaken for NEC or spontaneous perforation of Hirschsprung disease. [8,18,19,20] Abdominal distension, bilious vomiting, lethargy and thrombocytopenia are common to all the three conditions.…”

mentioning

confidence: 99%